Segment Information (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014 item segment	Mar. 31, 2013
Segment Information
Number of operating segments	1
Number of commercial products	3
Revenues, cost of revenues and gross profit
Revenues	$ 284,553	$ 243,146
Cost of revenues	30,273	29,313
Gross profit	254,280	213,833
Remodulin
Revenues, cost of revenues and gross profit
Revenues	136,106	114,681
Cost of revenues	13,226	13,406
Gross profit	122,880	101,275
Tyvaso
Revenues, cost of revenues and gross profit
Revenues	107,086	94,645
Cost of revenues	14,454	13,783
Gross profit	92,632	80,862
Adcirca
Revenues, cost of revenues and gross profit
Revenues	41,361	33,820
Cost of revenues	2,593	2,124
Gross profit	$ 38,768	$ 31,696